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use data
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Background: The most deﬁnitive outcome data on lower extremity amputation (LEA) comes from the Veterans
Administration (VA) system. Because of the unique nature of VA patients (more chronic disease, greater functional
disability, and lower socioeconomic status), it is not clear these results can be generalized to the private sector. This study
was undertaken to determine the short-term outcome of LEA in private sector patients and to deﬁne predictors of
operative mortality.
Methods: After Institutional Review Board approval and under the National Surgical Quality Improvement Program
public use agreement, a data set of LEA based on Current Procedural Terminology coding was assembled for the years
2005 to 2008. Patient demographics, comorbidities, and laboratory values were compiled and linked to operative
mortality. Dichotomous variables were analyzed using c2 test with odds ratios (ORs) and continuous variables with
Student t-test. Predictive modeling was done using stepwise logistic regression. Data were analyzed in SPSS.
Results: A total of 6839 patients underwent 4001 amputations below-knee (BK) and 2838 above-knee (AK) with a 9.1%
operative mortality (6.5% BK, 12.7% AK; P < .001). Age >60 years (OR, 2.4; 95% conﬁdence interval [CI], 1.9-2.9),
white race (OR, 1.2; 95% CI, 1.0-1.4), and American Society of Anesthesiologists classiﬁcation (II, 2.3% vs IV, 13.8%)
were signiﬁcant predictors of mortality. Preoperative functional status (20% for totally dependent vs 4.3% for indepen-
dent), renal failure (OR, 2.3; 95% CI, 1.7-3.2), and congestive heart failure (OR, 2.6; 95% CI, 2.1-3.3) also predicted
death. Postoperative complications associated with mortality included pneumonia (OR, 5.4; 95% CI, 4.1-7.0), ventilator
dependence (OR, 5.1; 95% CI, 3.8-6.8), and need for transfusion (OR, 3.7; 95% CI, 2.0-6.7). Hispanic and African-
American race (OR, 0.6; 95% CI, 0.4-0.9 and OR, 0.8; 95% CI, 0.7-1), history of peripheral arterial disease (OR, 0.6;
95% CI, 0.5-0.8), and smoking (OR, 0.5; 95% CI, 0.4-0.7) were protective (all ORs had P values < .001).
Conclusions: The mortality of LEA in private sector patients remains high, with risk factors similar to those identiﬁed in
previous studies of VA patients. These results should serve as a benchmark for future attempts to improve the outcome of
LEA and serve to improve patient and family counseling. (J Vasc Surg 2013;58:1276-82.)More than 100,000 major lower extremity amputations
(LEAs; amputations at the below-knee or above-knee level)
are performed yearly in theUnited States.1 Despite improve-
ments in long-term outcome, operative mortality following
LEA has remained stable at 9% to 10% over the last
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6treatment, the vascular surgical outcomes literature has
not been robust on LEA. The bulk of relevant studies consist
of case series with differences in era, region, and population
base. The most deﬁnitive outcome data on LEA to date
come from the Veterans Administration (VA) system using
the Veterans Affairs National Surgical Quality Improvement
Program (VA-NSQIP).3 Because of the unique nature of
VA patients (overwhelming male gender, higher burden of
chronic diseases, greater functional disability, and lower
socioeconomic status), it is not clear whether these results
can be generalized to the general population.
This study was undertaken to expand on this landmark
work by assessing its ﬁndings in a similar data set: The Amer-
ican College of Surgeons e National Surgical Quality
Improvement Program (ACS-NSQIP). The public use ﬁles
(PUFs) of ACS-NSQIP were used to explore multiple years
of public use data from a wide collection of heterogeneous
hospital settings. The PUF data set includes detailed peri-
operative information on a large number of private sector
patients, from non-VA hospitals, undergoing a variety of
surgical procedures, including LEA, with detailed, veriﬁed,
and audited outcomes, in addition to 30-day follow-up.
This data set was interrogated to determine the short-term
Table I. Patient demographics and comorbidities
Demographics and comorbidities % of population
Male (n ¼ 4182) 62
>60 years of age (n ¼ 4609) 67
Caucasian (n ¼ 4017) 58.7
African-American (n ¼ 1897) 27.7
Smokers (n ¼ 1928) 28
ASA IV (n ¼ 2667) 39
HTN (n ¼ 5601) 82
PAD (n ¼ 4625) 68
DM (n ¼ 4209) 61
Dialysis (n ¼ 1489) 21.8
CHF (n ¼ 589) 8.6
History of MI (n ¼ 401) 6
ASA, American Society of Anesthesiologists score; CHF, congestive heart
failure; DM, diabetes mellitus; HTN, hypertension; MI, myocardial infarc-
tion; PAD, peripheral arterial disease.
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possible predictors of operative mortality.
METHODS
After approval of the Institutional Review Board at
Henry Ford Hospital, and under the Data Use Agreement
of the ACS-NSQIP, 4 years of NSQIP data were obtained
(2005-2008). A uniﬁed data set was constructed assembling
all 4 years. Utilizing Current Procedural Terminology
(CPT) coding data based on primary case in the PUF data,
patients undergoing LEA were identiﬁed. Separate labels
were created based on amputation level, and analysis
was limited to above-knee (AKA) and below-knee
amputations (BKA) and the various CPT codes that
compromised these two groups. Comparisons of categorical
data were pursuedwith c2 and Fisher exact tests. Categorical
variables with more than two values (American Society of
Anesthesiologists [ASA] classiﬁcation, functional status, dia-
betes, dyspnea, preoperative wound infection, and type of
anesthesia used) were dichotomized into reference and
comparative variables. Continuous data comparisons were
completed using Student t-test and the Mann-Whitney
U test for nonparametric data. Predictive modeling was
pursued using logistic regression. Our multivariate analysis
was run using stepwise logistic regression. The criterion
for adding and removing predictors from the model was
P < .10. No variables were suspect for collinearity. Data
were analyzed in Excel (Microsoft, Redmond, Wash)
and SPSS (SPSS, Chicago, Ill). Signiﬁcance was deﬁned as
P < .05.
RESULTS
A total of 6839 patients who underwent either a BKA
(n ¼ 4001) or an AKA (n ¼ 2838) were identiﬁed between
2005 and 2008. Sixty-seven percent of patients were older
than 60 years, and 62% of the patients were males. Major
comorbidities reported included hypertension, peripheral
arterial disease (PAD), and diabetes mellitus. Demo-
graphics and preoperative clinical data are summarized in
Table I.
The overall 30-day mortality was 9.1% (n ¼ 622); 6.5%
(n ¼ 261) for BKA patients and 12.7% (n ¼ 361) for AKA
patients (odds ratio [OR], 2.1; 95% conﬁdence interval
[CI], 1.7-2.4; P < .001). The mean age of patients who
died within 30 days of surgery was 72.6 years; on univariate
analysis, age greater than 70 years had anOR for death of 1.8
(95% CI, 1.7-2.5) compared with an age less than 70 years
(Table II). African-American and Hispanic race seemed to
have a protective effect on mortality, with an OR of 0.8
(95% CI, 0.7-1; P < .001) and 0.6, respectively (95% CI,
0.4-0.9; P < .001), while being Caucasian carried a 20%
higher risk of dying following an amputation. Gender was
not found to have an effect on mortality. Smokers, both
current and those who smoked cigarettes within a year of
the procedure, died less frequently; 6% of smokers died
within 30 days postoperatively compared with 10.3% of
nonsmokers (OR, 0.5; 95% CI, 0.4-0.7; P < .001).ASA class was used as an indicator of overall patient
preoperative status; as might be expected, ASA 4 patients
had a 13.8% mortality rate, while ASA 5 patients had
a 53.6% mortality rate (P < .001). Speciﬁc comorbidities
were examined for their effect on 30-day mortality
(Table II). On univariate analysis, the most signiﬁcant
predictors of mortality were the presence of preoperative
pneumonia (OR, 3.6; 95% CI, 2.6-5.1; P < .001), conges-
tive heart failure (CHF) (OR, 2.6; 95% CI, 2.1-3.3; P <
.001), and acute renal failure (deﬁned as having a steadily
increasing azotemia and a rising creatinine of above 3 mg/
dL 24 hours prior to surgery), with an OR of 2.3 (95% CI,
1.7-3.2; P < .001). Being on dialysis had an OR of 2.1
(95% CI, 1.8-2.5; P < .001) for operative mortality, while
chronic obstructive pulmonary disease (COPD) carried an
OR of 1.8 (95% CI, 1.5-2.3; P < .001). Other factors with
a signiﬁcant positive correlation to mortality were dyspnea
at rest (P < .001), history of myocardial infarction (OR,
1.8; 95% CI, 1.3-2.4; P < .001), a history of stroke
(OR, 1.3; 95% CI, 1.0-1.6; P < .001), preoperative coa-
gulopathy (OR, 1.4; 95% CI, 1.2-1.7; P < .001), and
the presence of rest pain (OR, 1.2; 95% CI, 1.0-1.4;
P < .001). Looking more closely into cardiac risk, patients
with a history of coronary artery bypass fared worse than
those without (OR, 1.4; 95% CI, 1.1-1.7; P < .001).
A history of prior percutaneous cardiac intervention did
not affect outcome. Having a history of PAD conferred
a protective advantage from perioperative death (OR,
0.6; 95% CI, 0.5-0.8; P < .001). Eight percent of patients
with a history of PAD died compared with 11.4% of those
without. Preoperative functional status was also linked to
operative mortality; mortality among the totally dependent
patients was 20%, compared with 4.3% for independent
patients (P < .001). Patients who were not independent
had a three-fold increase in operative mortality. Patients
who had an amputation emergently had 90% higher
odds of dying than those who did not have an emergency
amputation (emergency case designation: OR, 1.9; 95%
CI, 1.5-2.3; P < .001). Patients who received a preopera-
tive blood transfusion (within 48 hours of surgery) had








Age >60 4097 (65.9) 512 (82.3) 2.4 (95% CI, 1.9-2.9) <.001
Male gender 3814 (61.4) 368 (59.2) 0.9 (95% CI, 0.7-1.0) .282
Caucasian 3626 (58.3) 391 (62.9) 1.2 (95% CI, 1.0-1.4) <.05
African-American 1739 (28.0) 158 (25.4) 0.8 (95% CI, 0.7-1) <.05
Hispanic 429 (6.9) 27 (4.3) 0.6 (95% CI, 0.4-0.9) <.05
Functional status, not independent 3708 (59.6) 508 (81.7) 3 (95% CI, 2.4-3.7) <.001
Smoker 1812 (29.1) 116 (18.6) 0.5 (95% CI, 0.4-0.7) <.001
Patient comorbidities
ASA IV and V 2331 (37.5) 400 (64.4) 3 (95% CI, 2.5-3.5) <.001
Dyspnea 1051 (16.9) 183 (29.4) 2 (95% CI, 1.7-2.4) <.001
CHF 476 (7.7) 113 (18.2) 2.6 (95% CI, 2.1-3.3) <.001
Renal failure 248 (4) 56 (9) 2.3 (95% CI, 1.7-3.2) <.001
History of MI 341 (5.5) 60 (9.6) 1.8 (95% CI, 1.3-2.4) <.001
Dialysis 1267 (20.4) 222 (35.7) 2.1 (95% CI, 1.8-2.5) <.001
Steroids 401 (6.5) 69 (11.1) 1.8 (95% CI, 1.3-2.3) <.001
COPD 713 (11.6) 124 (19.9) 1.8 (95% CI, 1.5-2.3) <.001
Previous PCI 888 (14.3) 100 (16.1) 1.1 (95% CI, 0.9-1.4) .225
Previous cardiac surgery 1459 (23.5) 188 (30.2) 1.4 (95% CI, 1.1-1.7) <.001
Rest pain 3982 (64.1) 429 (69) 1.2 (95% CI, 1.0-1.4) <.001
History of PAD 4255 (68.4) 370 (59.5) 0.6 (95% CI, 0.5-0.8) <.001
Current pneumonia 153 (2.5) 53 (8.5) 3.6 (95% CI, 2.6-5.1) <.001
HTN 5089 (81.9) 512 (82.3) 1.03 (95% CI, 0.8-1.2) .777
DM 3849 (61) 360 (57) 0.8 (95% CI, 0.7-0.9) .141
Preoperative wound infection 4706 (75.7) 454 (73) 0.8 (95% CI, 0.7-1) .143
History of stroke 921 (14.8) 117 (18.8) 1.3 (95% CI, 1.0-1.6) <.05
Bleeding disorder 1626 (26.2) 213 (34.2) 1.4 (95% CI, 1.2-1.7) <.001
Preoperative blood transfusion 41 (0.7) 15 (2.4) 3.7 (95% CI, 2.0-6.7) <.001
Sepsis 838 (13.5) 92 (14.8) 1.1 (95% CI, 0.8-1.4) <.001
Septic shock 197 (3.2) 82 (13.2) 4.5 (95% CI, 3.5-6.1) <.001
Surgery-speciﬁc factors
General anesthesia 5066 (81.5) 514 (82.6) 1 (95% CI, 0.8-1.3) .515
Emergency case 516 (8.3) 93 (14.7) 1.9 (95% CI, 1.5-2.3) <.001
ASA, American Society of Anesthesiologists score; CHF, congestive heart failure; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; DM,
diabetes mellitus; HTN, hypertension; MI, myocardial infarction; OR, odds ratio; PAD, peripheral artery disease; PCI, percutaneous coronary intervention.
JOURNAL OF VASCULAR SURGERY
1278 Karam et al November 2013three times higher odds of dying than those who did not
(OR, 3.7; 95% CI, 2.0-6.7; P < .001). Diabetes was not
found to be a signiﬁcant predictor of mortality. Wound
classiﬁcation and type of anesthesia did not affect
outcome. Table II summarizes the relationship between
patient demographics and comorbidities and operative
mortality.
The variables selected for our multivariate analysis were
race, gender, age more than 70 years, smoking history,
established diagnosis of PAD, history of renal failure, being
on dialysis, diabetes (whether on oral hypoglycemic or
insulin), emergency status of the surgery, history of
COPD, and CHF, and we grouped the ASA categories
into ASA of 4 and above and ASA of 3 and below. It was
interesting to notice that 40% of the patients in our dataset
had an ASA of 4 and above.
Our multivariate analysis conﬁrmed the negative asso-
ciation between black and Hispanic races with 30-day
mortality following LEA (OR, 0.7; 95% CI, 0.6-0.9 and
OR, 0.5; 95% CI, 0.3-0.8, respectively). This negative asso-
ciation was also present with a history of smoking (OR,
0.6; 95% CI, 0.4-0.8), an established diagnosis of PAD(OR, 0.6; 95% CI, 0.4-0.7), and diabetes (OR, 0.8; 95%
CI, 0.6-1). Factors that were associated with a higher
30-day mortality were being on dialysis (OR, 2.5; 95%
CI, 1.9-3.1), ASA >4 (OR, 2; 95% CI, 1.6-2.4), having
an AKA (OR, 1.9; 95% CI, 1.5-2.3), history of CHF
(OR, 1.9; 95% CI, 1.5-2.5), age >70 years (OR, 1.7;
95% CI, 1.3-2), COPD (OR, 1.7; 95% CI, 1.3-2.3), renal
failure (OR, 1.4; 95% CI, 0.9-2), and emergency status
designation of the LEA (OR, 1.4; 95% CI, 1-1.8). Results
are shown in Table III.
When examining the effect of postoperative complica-
tions on mortality, reintubation (deﬁned as any unplanned
intubation within 30 days of the operation) was the most
signiﬁcant predictor of mortality with an OR of 6.3 on
univariate analysis (95% CI, 4.1-9.2; P < .001). Postoper-
ative myocardial infarction carried a signiﬁcant increase
in mortality with an OR of 5.7 (95% CI, 3.2-10.1;
P < .001). Postoperative pneumonia, renal insufﬁciency
(deﬁned as a rise in creatinine of >2 mg/dL from preoper-
ative value), and stroke were also signiﬁcant predictors of
mortality. Table IV summarizes the relationship between
postoperative occurrences and mortality.
Table III. Multivariate analysis: patient demographics, comorbidities, and 30-day operative mortality
No. (% population)
Multivariate OR for
operative mortality (95% CI) Multivariate P value
Dialysis 1489 (21.8) 2.5 (1.9-3.1) <.001
ASA 4 and 5 2731 (39.9) 2 (1.6-2.4) <.001
CHF 589 (8.6) 1.9 (1.5-2.5) <.001
AKA 2838 (41.5) 1.9 (1.5-2.3) <.001
Age>70 2907 (42.5) 1.7 (1.3-2) <.001
COPD 847 (12) 1.7 (1.3-2.3) <.001
Preoperative renal failure 304 (4.4) 1.4 (0.9-2) .087
Emergency case 814 (11.9) 1.4 (1-1.8) .017
DM 4209 (61.5) 0.8 (0.6-1) .053
African-American 1894 (27.7) 0.7 (0.6-0.9) .005
Smoker 1928 (28.2) 0.6 (0.4-0.8) .002
PAD 4625 (67.6) 0.6 (0.4-0.7) <.001
Hispanic 456 (6.6) 0.5 (0.3-0.8) .009
AKA, Above-knee-amputation; ASA, American Society of Anesthesiologists score; CHF, congestive heart failure; CI, conﬁdence interval; COPD, chronic
obstructive pulmonary disease; DM, diabetes mellitus; PAD, peripheral artery disease.
Table IV. Postoperative complications and 30-day mortality
Alive at 30 days
(n ¼ 6217)
Dead at 30 days
(n ¼ 622) Univariate OR
Univariate
P value
Reintubation 2% (n ¼ 249) 20% (n ¼ 124) 6.3 (95% CI, 4.1-9.2) <.001
Pneumonia 3% (n ¼ 187) 14% (n ¼ 87) 5.4 (95% CI, 4.1-7.0) <.001
MI 0.5% (n ¼ 31) 3% (n ¼ 19) 5.7 (95% CI, 3.2-10.1) <.001
Stroke 0.5% (n ¼ 32) 2% (n ¼ 12) 4.7 (95% CI, 2.6-8.3) <.001
Ventilator dependence 2% (n ¼ 124) 12% (n ¼ 74) 5.1 (95% CI, 3.8-6.8) <.001
Acute renal failure 1% (n ¼ 63) 5% (n ¼ 31) 5.2 (95% CI, 3.4-7.9) <.001
CI, Conﬁdence interval; MI, myocardial infarction; OR, odds ratio.
Ventilator dependence: Mechanical ventilation >48 hours postoperation.
Acute renal failure: Worsening of renal dysfunction postoperatively requiring hemodialysis, peritoneal dialysis, hemoﬁltration, hemodiaﬁltration, or ultraﬁl-
tration within 30 days of the operation.
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between patients undergoing an AKA and those having
a BKA, patient demographics and comorbidities and their
effect on operative mortality were compared between the
two groups. Older patients seemed more likely to get an
AKA; for patients older than 70 years, the OR for getting
an AKA was 1.8 (95% CI, 1.6-2.0; P < .001). Males
were more likely to get a BKA (OR, 0.64 for AKA), while
African-Americans were more likely to get an AKA (OR,
1.2; 95% CI, 1.1-1.3). A patient with an ASA of 5 was
more likely to get an AKA compared with a patient with
a lower ASA classiﬁcation. Diabetics were more prone to
receive a BKA (68% vs 51.4%; P < .001). Dyspnea at rest
was also linked to AKA (6.6% vs 4.6%; P < .001). A totally
dependent patient was more likely to get an AKA than
a BKA (28.7% vs 11.2%; P < .001). A patient with
COPD was more likely to receive an AKA (15.1% vs
10.5%; P < .001). Being on dialysis was associated with
a higher BKA rate compared with AKA (23.1% vs 19.9%;
P < .001). This was also seen in patients with PAD
(68.8% vs 66%; P ¼ .015). Table V summarizes patient
demographics and comorbidities in BKA vs AKA patients.
When examining postoperative complications in BKA
and AKA patients, the pulmonary embolism (PE) ratewas found to be 73% higher in the AKA group compared
with the BKA group (1.9% vs 1.1%; P < .05). Failure to
wean (deﬁned as being on mechanical ventilation for
more than 48 hours postoperatively) was more common
in AKA patients (6.6% vs 3.7%; P < .001). A stroke was
also more likely to occur post-AKA (1.3% vs 0.4%;
P < .001). Deep wound infections and wound dehiscence
were less likely to occur after AKA (3.6% vs 2.4%; P < .001
for infection; 1.9% vs 1.1%; P < .001 for dehiscence).
Table VI summarizes the key differences in preoperative
characteristics and postoperative morbidities in BKA vs
AKA.
DISCUSSION
This study, compiled from NSQIP-participating hospi-
tals from 2005 to 2008, includes 6839 patients and is one
of the largest in the literature. The most deﬁnitive outcome
data on LEA comes from the VA system, with a homoge-
neous, predominantly male population with access to
medical care.1,3,5,7 A distinctive aspect of our population
sample is that it is taken from the private sector, with
women representing 38% of the population, a population
that is diverse in ethnicity, morbidities, and socio-
economic status. The goal of the study is to validate the
Table V. Patient demographics and comorbidities in BKA vs AKA patients
AKA (n ¼ 2828) BKA (n ¼ 4001) Univariate OR P value
Male gender 54.9% (n ¼ 1552) 65.6% (n ¼ 2625) 0.6 (95% CI, 0.5-0.7) <.001
Age >70 51.1% (n ¼ 1449) 36.4% (n ¼ 1456) 1.8 (95% CI, 1.6-2.0) <.001
African-American 3.4% (n ¼ 860) 25.9% (n ¼ 1036) 1.2 (95% CI, 1.1-1.3) <.001
Functional status, totally dependent 28.7% (n ¼ 811) 11.2% (n ¼ 448) NAa <.001
ASA IV 45.7% (n ¼ 1292) 34.5% (n ¼ 1380) NAa <.001
ASA V 1.2% (n ¼ 34) 0.6% (n ¼ 24) NAa <.001
PAD 66% (n ¼ 1866) 68.8% (n ¼ 2753) .8 (95% CI, 0.7-0.9) .015
DM 51.4% (n ¼ 1453) 68% (n ¼ 2721) NAa <.001
Dyspnea at rest 6.6% (n ¼ 187) 4.6% (n ¼ 185) NAa <.001
COPD 15.1% (n ¼ 427) 1.5% (n ¼ 420) 1.5 (95% CI, 1.3-1.7) <.001
Dialysis 19.9% (n ¼ 562) 23.1% (n ¼ 924) .8 (95% CI, 0.7-0.9) <.001
Wound infection 15.3% (n ¼ 433) 15.8% (n ¼ 632) .7 (95% CI, 0.7-0.8) .265
Emergency case 12.8% (n ¼ 362) 11.3% (n ¼ 452) 1.1 (95% CI, 0.9-1.3) <.05
AKA, Above-knee-amputation; ASA, American Society of Anesthesiologists score; BKA, below-knee-amputation; CI, conﬁdence interval; COPD, chronic
obstructive pulmonary disease; DM, diabetes mellitus; OR, odds ratio; PAD, peripheral artery disease.
aVariables with no OR available are variables with more than two values in the NSQIP database.
Table VI. Postoperative outcome in BKA vs AKA patients
AKA (n ¼ 2838) BKA (n ¼ 4001) Univariate OR P value
Mortality 12.7% (n ¼ 361) 6.5% (n ¼ 260) 2.1 (95% CI, 1.7-2.4) <.001
Wound dehiscence 1.1% (n ¼ 32) 1.9% (n ¼ 77) 0.5 (95% CI, 0.4-0.7) <.05
Pulmonary embolus 0.8% (n ¼ 23) 0.4% (n ¼ 16) 2.1 (95% CI, 1.8-2.3) <.05
Failure to wean 6.6% (n ¼ 187) 3.7% (n ¼ 148) 1.8 (95% CI, 1.4-2.2) <.001
CVA 1.3% (n ¼ 37) 0.4% (n ¼ 16) 2.8 (95% CI, 1.6-5.0) <.001
Deep incision SSI 2.4% (n ¼ 69) 3.6% (n ¼ 145) 0.6 (95% CI, 0.4-0.8) <.001
Acute renal failure 1.3% (n ¼ 38) 1.5% (n ¼ 60) 0.8 (95% CI, 0.5-1.2) .232
MI .7% (n ¼ 20) 0.8% (n ¼ 32) 0.9 (95% CI, 0.5-1.6) .448
AKA, Above-knee-amputation; BKA, below-knee-amputation; CI, conﬁdence interval; CVA, cardiovascular accident; MI, myocardial infarction; SSI, surgical
site infection.
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signiﬁcant predictors of operative mortality following
LEA in the private sector.
The operative mortality rate for LEA in this study was
9.1%; 6.5% for BKA and 12.7% for AKA. These rates are
consistent with the most recently published data from
both the VA system and single institution studies.1,4-8
The population sample of the current study differs
signiﬁcantly from the VA papers in that it includes a large
number of women. Analysis of this data validates the fact
that gender had no effect on operative mortality.1 The
effect of advancing age on operative mortality is also high-
lighted in this paper, as has been well established by
multiple previous studies.9
The counterintuitive protective effect of being a smoker
at the time of an LEA has been also previously described in
VA data.9 We can postulate that being a smoker at the time
of surgery might mean that one is healthy enough to still
do so. Smoking could also correlate with a diagnosis of
PAD; however, only 20% of the patients in this study
were both smokers and had a diagnosis of PAD. A more
accurate quantitative measure of the deleterious effect of
smoking on surgical outcome should be used.
African-Americans represented 27.7% of our patients,
one of the largest sample sizes in the literature studying
LEA. The effect of race on outcome is controversial. Ina VA study, Collins and colleagues concluded that race
did not impact 30-day survival.3 In a paper looking into
racial disparities in LEA, Regenbogen et al analyzed elderly
Medicare beneﬁciaries and found that African-Americans
were more likely to undergo LEA than Caucasian patients
(45% vs 20%), and had less endovascular procedures per-
formed on them (46% vs 51%). This has been attributed
to lack of access to medical and specialist care. African-
Americans were also more likely to have an AKA,10
a ﬁnding conﬁrmed in the current study. However,
African-Americans and Hispanics had improved outcomes
compared with Caucasians after LEA in this study;
this was similar to a paper by Feinglass et al.9 It is difﬁcult
to explain this survival beneﬁt; a closer look into patient
speciﬁc demographics such as age at amputation,
prior revascularization attempts, and indications for ampu-
tations are warranted for a better understanding of this
ﬁnding.
Independent predictors of operative mortality are
mostly predictors of perioperative cardiac events, those
being the most common causes of mortality.6 The main
independent predictors of perioperative cardiac events
were described by Lee et al and are CAD, CHF, cerebro-
vascular disease, high risk surgery, and creatinine >2.11
We used the list of preoperative morbidities available
through the NSQIP data set and linked each item to
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Volume 58, Number 5 Karam et al 1281operative mortality. We found no signiﬁcant differences
between the factors identiﬁed as signiﬁcant predictors of
mortality in the VA system and those identiﬁed in the
current study. In fact, VA data show that myocardial infarc-
tion, respiratory complications,12 being on dialysis, preop-
erative pneumonia, and ASA class 4 or 5, as well as totally
dependent functional status are important predictors of
mortality.9 We found these results to be valid in the private
sector population.
Despite being associated with an increased rate of
LEA,13 in most studies reviewed, diabetes mellitus has
not been linked to an increase in operative mortality,6,14,15
a ﬁnding corroborated in this study. Appropriate glycemic
control at the time of amputation did not affect outcome.16
Diabetics going through an amputation are generally
younger than nondiabetics; they are also more prone to
frequent postoperative hospitalization, and more likely to
progress to higher levels of amputation.17 However, dia-
betes has been consistently shown to be a strong predictor
of long-term mortality.6,16,18,19
Fewer than 15% of major LEAs are traumatic in origin;
vasculopathy and infection are the most common causes
leading to an LEA.20,21 We found that having an estab-
lished diagnosis of PAD, with a history of peripheral arterial
revascularization conferred a protective advantage from
operative mortality, as did previously published data look-
ing into this variable.9 We think that the care of a patient
with an established diagnosis of PAD involves closer,
more frequent follow-up and preventive modalities, as
well as a higher index of suspicion for signs of ischemia
and infection. Foot ulcers are a remarkable example. Foot
ulcers are responsible for more than 50% of amputa-
tions,16,22,23 and can be prevented by up to 78% with early
identiﬁcation and effective management,18,24 leading to
inevitable drop in amputation rates.13,25
Many studies have also shown a decrease in rates of
amputations with aggressive revascularization, whether
bypass surgeries or endovascular procedures.26-28 In fact,
these procedures have doubled over the past decade,
with a signiﬁcant drop in rates of amputation as high as
30%.29
The idea that an amputation is a faster, easier alterna-
tive to lower extremity revascularization is erroneous. In
fact, 30-day mortality of peripheral vascular bypass is close
to the one attributed to amputations.30 Looking at the
long-term mortality numbers as published by Landry
et al, bypass proves to be more advantageous.31
Patients with PAD and diabetes typically have progres-
sion of disease and are at risk of reamputation and revisions
to higher level amputations.17,29 In a study by Dillingham
et al, reamputation rates have been found to be 19.7% for
BKA and 12% for AKA.17 Below-knee reamputation rates
were also found to be as high as 30%.32 A lower level of
amputation is advantageous in terms of operative mortality,
but one should bear in mind reamputation rates and the
possible additive effect on mortality.
One of the major limitations of our study is the
inability to accurately provide the indications for patientsin our dataset. In fact, just like the VA database, the
NSQIP database is an administrative one, with no speciﬁc
indication variable that can be used with accuracy.
CONCLUSIONS
In this study, we conﬁrmed the previously published
data on predictors of mortality in LEA, data mostly coming
from the VA system. We are able to adequately risk
stratify and identify patients at higher risk from an adverse
outcome going for an amputation. Taking into account
these speciﬁc patient characteristics, morbidities, and post-
operative occurrences, we can better counsel a patient candi-
date for an amputation. On the other hand, advances in
endovascular interventions as well as more aggressive
surgical revascularization have led to a decrease in amputa-
tion rates; perhaps a more aggressive approach in the
treatment of critical limb ischemia would be another way
to reduce the burden of morbidity and mortality that
amputations pose on patients.
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